These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 19450649)

  • 1. Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice.
    Voltan R; Castaldello A; Brocca-Cofano E; De Michele R; Triulzi C; Altavilla G; Tondelli L; Laus M; Sparnacci K; Reali E; Gavioli R; Ensoli B; Caputo A
    Vaccine; 2009 Jul; 27(33):4498-507. PubMed ID: 19450649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination.
    Castaldello A; Brocca-Cofano E; Voltan R; Triulzi C; Altavilla G; Laus M; Sparnacci K; Ballestri M; Tondelli L; Fortini C; Gavioli R; Ensoli B; Caputo A
    Vaccine; 2006 Jul; 24(29-30):5655-69. PubMed ID: 16781023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
    Cristillo AD; Wang S; Caskey MS; Unangst T; Hocker L; He L; Hudacik L; Whitney S; Keen T; Chou TH; Shen S; Joshi S; Kalyanaraman VS; Nair B; Markham P; Lu S; Pal R
    Virology; 2006 Mar; 346(1):151-68. PubMed ID: 16325880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat.
    Caputo A; Gavioli R; Altavilla G; Brocca-Cofano E; Boarini C; Betti M; Castaldello A; Lorenzini F; Micheletti F; Cafaro A; Sparnacci K; Laus M; Tondelli L; Ensoli B
    Vaccine; 2003 Mar; 21(11-12):1103-11. PubMed ID: 12559787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.
    Buonaguro L; Devito C; Tornesello ML; Schröder U; Wahren B; Hinkula J; Buonaguro FM
    Vaccine; 2007 Aug; 25(32):5968-77. PubMed ID: 17629365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
    Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
    Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.
    Gavioli R; Cellini S; Castaldello A; Voltan R; Gallerani E; Gagliardoni F; Fortini C; Cofano EB; Triulzi C; Cafaro A; Srivastava I; Barnett S; Caputo A; Ensoli B
    Vaccine; 2008 Jan; 26(5):727-37. PubMed ID: 18096278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
    Jiang W; Ren L; Jin N
    J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
    Turbant S; Martinon F; Moine G; Le Grand R; Léonetti M
    Vaccine; 2009 Aug; 27(39):5349-56. PubMed ID: 19607953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting.
    Li W; Li S; Hu Y; Tang B; Cui L; He W
    Vaccine; 2008 Jun; 26(26):3282-90. PubMed ID: 18472194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon regulatory factor-1 acts as a powerful adjuvant in tat DNA based vaccination.
    Castaldello A; Sgarbanti M; Marsili G; Brocca-Cofano E; Remoli AL; Caputo A; Battistini A
    J Cell Physiol; 2010 Sep; 224(3):702-9. PubMed ID: 20432465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cationic polymers that enhance the performance of HbsAg DNA in vivo.
    Bos GW; Kanellos T; Crommelin DJ; Hennink WE; Howard CR
    Vaccine; 2004 Dec; 23(4):460-9. PubMed ID: 15530694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
    Hinkula J; Walther-Jallow L; Laurén A; Mäkitalo B; Oberg M; Wahren B; Fenyö EM; Spetz AL
    Vaccine; 2009 Oct; 27(46):6424-31. PubMed ID: 19549607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating specific priming of immune effector functions by DNA-based vaccination strategies.
    Reimann J; Schirmbeck R
    Dev Biol (Basel); 2000; 104():15-24. PubMed ID: 11713813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules.
    Fraternale A; Paoletti MF; Dominici S; Buondelmonte C; Caputo A; Castaldello A; Tripiciano A; Cafaro A; Palamara AT; Sgarbanti R; Garaci E; Ensoli B; Magnani M
    Vaccine; 2011 Sep; 29(40):6823-9. PubMed ID: 21816192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy.
    Stambas J; Brown SA; Gutierrez A; Sealy R; Yue W; Jones B; Lockey TD; Zirkel A; Freiden P; Brown B; Surman S; Coleclough C; Slobod KS; Doherty PC; Hurwitz JL
    Vaccine; 2005 Mar; 23(19):2454-64. PubMed ID: 15752831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses.
    Huang X; Liu L; Ren L; Qiu C; Wan Y; Xu J
    Vaccine; 2007 Dec; 25(52):8874-84. PubMed ID: 18061316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prime-boost strategies in DNA vaccines.
    Dale CJ; Thomson S; De Rose R; Ranasinghe C; Medveczky CJ; Pamungkas J; Boyle DB; Ramshaw IA; Kent SJ
    Methods Mol Med; 2006; 127():171-97. PubMed ID: 16988455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine.
    Jamali A; Mahdavi M; Hassan ZM; Sabahi F; Farsani MJ; Bamdad T; Soleimanjahi H; Motazakker M; Shahabi S
    Int Immunol; 2009 Mar; 21(3):217-25. PubMed ID: 19174474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.